Imara Inc. (IMRA) News
Filter IMRA News Items
IMRA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest IMRA News From Around the Web
Below are the latest news stories about IMARA INC that investors may wish to consider to help them evaluate IMRA as an investment opportunity.
Imara 10% Owner Trades $336K In Company StockRA CAPITAL MANAGEMENT, L.P. , 10% Owner at Imara (NASDAQ: IMRA ), reported a large insider buy on October 24, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that L.P. purchased 85,902 shares of Imara. The total transaction amounted to $336,811. Imara shares are trading up 2.75% at $4.64 at the time of this writing on Tuesday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used primarily to make … Full story available on Benzinga.com |
At What Point In Time Would I Choose To Purchase IMARA Inc. (NASDAQ: IMRA) Stock?The trading price of IMARA Inc. (NASDAQ:IMRA) closed higher on Monday, October 24, closing at $4.52, 15.31% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $3.86 and $4.76. In examining the 52-week price action we see that the stock hit a 52-week high … At What Point In Time Would I Choose To Purchase IMARA Inc. (NASDAQ: IMRA) Stock? Read More » |
Dow Rises 1.5%; Nasdaq Jumps Over 100 PointsU.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 450 points on Monday. The Dow traded up 1.50% to 31,547.65 while the NASDAQ rose 1.04% to 10,972.47. The S&P 500 also rose, gaining, 1.38% to 3,804.48. Also check this: Market Volatility Decreases As Dow Jumps More Than 700 Points Leading and Lagging Sectors Health care shares climbed 2.1% on Monday. Leading the sector was strength from Vaxcyte, Inc. (NASDAQ: PCVX ) and IMARA Inc. (NASDAQ: IMRA ). In trading on Monday, materials shares fell by 0.3%. Top Headline The S&P Global manufacturing PMI dropped to 49.9 in October from 52 in September, down from market estimates of 51. US services PMI fell to 46.6 in October from 49.3 in the prior month. Equities Trading UP Vaxcyte, Inc. (NASDAQ: PCVX ) shar... |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMRA, SBTX, COWN, JVA, HVBCNEW YORK, Oct. 20, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Imara Inc. (NASDAQ: IMRA)''s merger with… |
Struggling blood disorder biotech shuts down via reverse mergerImara Inc., the blood disorder-focused company that earlier this year cut its staff to just six people, will be no more following a reverse merger with a Colorado biotech. |
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Crinetics Pharmaceuticals (CRNX) and IMARA (IMRA)Analysts have been eager to weigh in on the Healthcare sector with new ratings on Inovio Pharmaceuticals (INO – Research Report), Crinetics Pharmaceuticals (CRNX – Research Report) and IMARA (IMRA – Research Report). Inovio Pharmaceuticals (INO) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals. The company's shares closed last Thursday at $1.70, close to its 52-week low of $1.38. According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -24.5% and a 23.9% success rate. |
Imara Merging With Enliven, Shares PopShares of Imara (NASDAQ: IMRA) popped on Friday in morning trading after the company announced its merger with Enliven Therapeutics, a clinical-stage precision oncology company. Imara is focused on the development and commercialization of novel therapeutics to treat patients suffering from serious diseases. This merger is expected to create a publicly-listed clinical-stage biopharmaceutical company that will be focused on advancing Enliven’s portfolio of precision oncology programs. The combined company is expected to have a cash balance of around $300 million at the close of the merger. This merger is expected to "provide cash runway through multiple clinical milestones and into early 2026. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGet ready for one more day of trading this week as we break down the biggest pre-market stock movers for Friday morning! |
Imara (IMRA) Stock Soars 35% on Merger AgreementImara (MRA) stock is rocketing higher on Friday after the company revealed plans for a merger agreement with Enliven Therapeutics. |
What Is Going on With Castellum (CTM) Stock Today?Castellum (CTM) stock is on the move Friday as recent volatility follows the shares going through an uplisting yesterday. |